Would the diagnosis of skin-only morphea (localized scleroderma) alter treatment recommendations for localized anal cancer?

There is enough data about the acute and late toxicity from radiation in these patients to be concerned. However, none of it rises to the level of the toxicity of APR. Therefore, my approach would be to involve the patient in the decision, document, and reduce the dose by 10%.